Status:
COMPLETED
Study for Atrial Fibrillation Reduction (SAFARI)
Lead Sponsor:
Medtronic Cardiac Ablation Solutions
Conditions:
Atrial Fibrillation, Bradycardia
Eligibility:
All Genders
Phase:
NA
Brief Summary
Atrial fibrillation (AF), which is the name for rapid beats in the upper chambers of the heart, is the world's most common kind of irregular heart beat. People with AF experience symptoms such as hear...
Eligibility Criteria
Inclusion
- Subjects with a slow heartbeat who are in need of dual chamber pacing (pacing in both the atrium and ventricle).
- Subjects who have experienced at least two episodes of rapid heart beats three months prior to enrollment.
Exclusion
- Subjects who have a history of permanent (chronic) or persistent (non self-terminating) atrial fibrillation.
- Subjects with atrial fibrillation due to reversible cause, (e.g. thyroid disease, pericarditis, post-surgery, alcohol abuse).
- Subjects with a history of one or more cardioversions (changing an abnormal heart rhythm into a normal one by either using medication or by the application of an electric shock) six months prior to enrollment.
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 21 2006
Estimated Enrollment :
540 Patients enrolled
Trial Details
Trial ID
NCT00267137
Start Date
September 1 2002
End Date
July 21 2006
Last Update
February 13 2025
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Yuma, Arizona, United States
2
Fayetteville, Arkansas, United States
3
Fort Smith, Arkansas, United States
4
Bakersfield, California, United States